

Saranya Sridhar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4438935/publications.pdf>

Version: 2024-02-01

40
papers

2,795
citations

304368

22
h-index

288905

40
g-index

42
all docs

42
docs citations

42
times ranked

5018
citing authors

#	ARTICLE	IF	CITATIONS
1	CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals. <i>Clinical Infectious Diseases</i> , 2021, 72, 1730-1737.	2.9	5
2	The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States. <i>Journal of Infectious Diseases</i> , 2020, 221, 1057-1069.	1.9	6
3	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. <i>PLoS ONE</i> , 2020, 15, e0234236.	1.1	9
4	Diabetes mellitus and latent tuberculosis infection: baseline analysis of a large UK cohort. <i>Thorax</i> , 2019, 74, 91-94.	2.7	17
5	Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. <i>EBioMedicine</i> , 2018, 29, 146-154.	2.7	100
6	Prime and target immunization protects against liver-stage malaria in mice. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	68
7	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, 49.	2.9	51
8	Prognostic value of interferon- γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1077-1087.	4.6	135
9	Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years. <i>Npj Vaccines</i> , 2018, 3, 37.	2.9	13
10	Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. <i>New England Journal of Medicine</i> , 2018, 379, 327-340.	13.9	557
11	Boosting of Cross-Reactive and Protection-Associated T Cells in Children After Live Attenuated Influenza Vaccination. <i>Journal of Infectious Diseases</i> , 2017, 215, 1527-1535.	1.9	45
12	Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines. <i>Frontiers in Immunology</i> , 2016, 7, 195.	2.2	85
13	Evaluation of serum inflammatory biomarkers as predictors of treatment outcome in pulmonary tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1653-1660.	0.6	13
14	Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination. <i>Journal of Infectious Diseases</i> , 2016, 215, jiw619.	1.9	27
15	Reply. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1138.	1.1	0
16	Longevity and Determinants of Protective Humoral Immunity after Pandemic Influenza Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 325-332.	2.5	23
17	Ebola and Marburg vaccines for Africa: one step closer. <i>Lancet</i> , The, 2015, 385, 1491-1493.	6.3	4
18	Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. <i>Vaccines</i> , 2015, 3, 373-389.	2.1	151

#	ARTICLE	IF	CITATIONS
19	Screening for latent tuberculosis before tumour necrosis factor antagonist therapy. <i>European Respiratory Journal</i> , 2015, 45, 1510-1512.	3.1	4
20	Vitamin D deficiency and TB disease phenotype. <i>Thorax</i> , 2015, 70, 1171-1180.	2.7	31
21	Clinical development of Ebola vaccines. <i>Therapeutic Advances in Vaccines</i> , 2015, 3, 125-138.	2.7	65
22	Harnessing local and systemic immunity for vaccines against tuberculosis. <i>Mucosal Immunology</i> , 2014, 7, 20-26.	2.7	69
23	Increased Risk of Mycobacterium tuberculosis Infection in Household Child Contacts Exposed to Passive Tobacco Smoke. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 1303-1306.	1.1	8
24	A rare success for cholera vaccines. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 1000-1001.	4.6	3
25	Cellular immune correlates of protection against symptomatic pandemic influenza. <i>Nature Medicine</i> , 2013, 19, 1305-1312.	15.2	757
26	Tuberculosis vaccines: time to reset the paradigm?: Table 1. <i>Thorax</i> , 2013, 68, 1092-1094.	2.7	22
27	Incidence of Influenza A(H1N1)pdm09 Infection, United Kingdom, 2009-2011. <i>Emerging Infectious Diseases</i> , 2013, 19, 1866-1869.	2.0	7
28	Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype. <i>Thorax</i> , 2013, 68, 221-229.	2.7	55
29	Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF- α antagonist therapy. <i>Thorax</i> , 2013, 68, 955-961.	2.7	29
30	A Comparison between Two Strategies for Monitoring Hepatic Function during Antituberculous Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 653-659.	2.5	44
31	Innate Immunity to TB: A Druggable Balancing Act. <i>Cell</i> , 2012, 148, 389-391.	13.5	9
32	Predominance of heterosubtypic γ -IFN α 3 α only α secreting effector memory T cells in pandemic H1N1/2009 NA1 naive adults. <i>European Journal of Immunology</i> , 2012, 42, 2913-2924.	1.6	34
33	Sarcoidosis and Tuberculosis Cytokine Profiles: Indistinguishable in Bronchoalveolar Lavage but Different in Blood. <i>PLoS ONE</i> , 2012, 7, e38083.	1.1	31
34	Redefining latent tuberculosis. <i>Future Microbiology</i> , 2011, 6, 1021-1035.	1.0	24
35	BCG vaccination: 90 years on and still so much to learn <i>Thorax</i> , 2010, 65, 1036-1038.	2.7	23
36	Enumeration of Functional T-Cell Subsets by Fluorescence-Immunospot Defines Signatures of Pathogen Burden in Tuberculosis. <i>PLoS ONE</i> , 2010, 5, e15619.	1.1	74

#	ARTICLE	IF	CITATIONS
37	An affordable cholera vaccine: an important step forward. <i>Lancet</i> , The, 2009, 374, 1658-1660.	6.3	4
38	Single-Dose immunogenicity and protective efficacy of simian adenoviral vectors against <i>Plasmodium berghei</i> . <i>European Journal of Immunology</i> , 2008, 38, 732-741.	1.6	95
39	Single-Dose Protection against <i>Plasmodium berghei</i> by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A. <i>Journal of Virology</i> , 2008, 82, 3822-3833.	1.5	67
40	A Novel Multi-Antigen Virally Vected Vaccine against <i>Mycobacterium avium</i> Subspecies paratuberculosis. <i>PLoS ONE</i> , 2007, 2, e1229.	1.1	29